Ticker
CRSP

Price
54.50
Stock movement up
+0.16 (0.29%)
Company name
Crispr Therapeutics AG
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
4.22B
Ent verdi
3.90B
Pris/omsetning
4.61
Pris/bok
1.88
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
13.55
Fremtidig P/E
-
PEG
-
EPS-vekst
54.00%
1 års avkastning
-29.08%
3 års avkastning
-9.34%
5 års avkastning
23.47%
10 års avkastning
-
Sist oppdatert: 2022-12-05

UTBYTTE

CRSP betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E13.55
Pris til OCF8.37
Pris til FCF10.19
Pris til EBITDA12.50
EV i forhold til EBITDA11.54

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning4.61
Pris til bok1.88
EV i forhold til salg4.26

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall77.46M
EPS (TTM)4.07
FCF per aksje (TTM)5.41

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)915.36M
Bruttofortjeneste (TTM)914.42M
Driftsinntekter (TTM)312.10M
Netto inntekt (TTM)311.61M
EPS (TTM)4.07
EPS (1 år fremover)-7.57

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)99.90%
Driftsmargin (TTM)34.10%
Fortjenestemargin (TTM)34.04%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter683.91M
Netto fordringer143.00K
Samlede omløpsmidler2.26B
Goodwill0.00
Immaterielle eiendeler112.00K
Eiendom, anlegg og utstyr0.00
Sum eiendeler2.61B
Leverandørgjeld27.11M
Kortsiktig/nåværende langsiktig gjeld238.98M
Sum kortsiktig gjeld113.70M
Sum gjeld361.26M
Aksjonærenes egenkapital2.24B
Netto varige driftsmidler2.24B

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)504.40M
Kapitalutgifter (TTM)90.03M
Fri kontantstrøm (TTM)414.37M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning13.88%
Avkastning på eiendeler11.96%
Avkastning på investert kapital13.81%
Kontantavkastning på investert kapital18.37%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning53.33
Daglig høy54.68
Daglig lav52.63
Daglig volum742K
Tidenes høyeste210.04
1 år analytikerestimat114.48
Beta1.91
EPS (TTM)4.07
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon14 Feb 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
CRSPS&P500
Nåværende prisfall fra toppnotering-74.05%-14.82%
Høyeste prisfall-79.42%-56.47%
Dato for høyeste fall9 May 20229 Mar 2009
Gj.snittlig fall fra topp-34.62%-11.46%
Gj.snittlig tid til ny topp26 days13 days
Maks tid til ny topp520 days1805 days
SELSKAPSOPPLYSNINGER
CRSP (Crispr Therapeutics AG) company logo
Markedsverdi
4.22B
Markedsverdi kategori
Mid-cap
Beskrivelse
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Ansatte
473
Investorrelasjoner
SEC-innsendelser
Adm. direktør
Samarth Kulkarni
Land
USA
By
Zug
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Three good examples are Teladoc Health (NYSE: TDOC), Nike (NYSE: NKE), and Crispr Therapeutics (NASDAQ: CRSP). Two billion-dollar noncash goodwill impairment charges hurt Teladoc's earnings this year...
December 6, 2022
In this article, we discuss the 13 best genomics stocks to buy now. If you want to read about some more genomics stocks, go directly to 5 Best Genomics Stocks To Buy Now. Before talking about the best...
December 5, 2022
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
December 1, 2022
ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea...
December 1, 2022
Investing in biotech companies, especially relatively small ones, can be a double-edged sword. With that in mind, let's look at two gene-editing-focused biotechs that could perform substantially bett...
November 17, 2022
Crispr Therapeutics (NASDAQ: CRSP) may be about to prove the strength of its gene-editing technology. The biotech company is submitting its candidate to treat blood disorders to regulators in the U.S...
November 15, 2022
In this piece, we will take a look at the ten most promising gene therapy companies to watch. For more companies, take a look at 5 Most Promising Gene Therapy Companies to Watch. Gene therapy is a rev...
November 14, 2022
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
November 12, 2022
ZUG, Switzerland and BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea...
November 10, 2022
Often, healthcare stocks outperform because investors know people can't avoid buying their medications or undergoing a medical procedure. Today, though, many healthcare stocks are heading for an annu...
November 9, 2022
Neste side